Q32 Bio is developing drugs targeting powerful regulators of both the innate and adaptive immune systems with the goal of re-balancing the immune system.

Q32 Bio’s pipeline programs are regulating and rebalancing the immune system to improve the lives of patients with severe inflammatory and autoimmune diseases.

Jason Campagna, Chief Medical Officer of Q32 Bio, has more than 15 years of leadership experience with a focus on advancing clinical development and pipeline efforts at leading biopharmaceutical companies.

Nov 16, 2023 · — Q32 Bio now wholly owns development and commercialization rights to the anti-IL-7Rα antibody, currently being evaluated in two Phase 2 trials for atopic dermatitis (AD) and alopecia areata (AA) — — Re-acquisition bolsters Q32 Bio’s autoimmune product portfolio and broadens strategic opportunities — WALTHAM, Mass. – Nov. 16, 2023 ...

Q32 Bio is pioneering a platform underpinned by a new approach to treating complement-mediated diseases by targeting our drugs directly to the affected tissue, while allowing for the other important functions of complement to remain largely unimpaired.

May 27, 2020 · Q32 Bio’s proprietary and unique platform has yielded a pipeline of novel protein therapeutics that provide potent inhibition of complement in diseased tissues without long-term systemic blockade – a key differentiator versus current complement therapeutics.

May 26, 2022 · Q32 Bio’s lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.

Oct 29, 2020 · Q32 Bio’s lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.

Aug 15, 2022 · Q32 Bio’s lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.